A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2018
At a glance
- Drugs HD-204 (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Prestige BioPharma
- 03 Apr 2018 Planned End Date changed from 1 Jun 2020 to 1 Feb 2021.
- 03 Apr 2018 Planned primary completion date changed from 1 Jan 2020 to 1 Nov 2020.
- 03 Apr 2018 Planned initiation date changed from 1 Jan 2018 to 1 Nov 2018.